Figure 2. Active compounds treatment reduces ultrastructural impairment and decreases Aβ-42 expression in the AD model mouse frontal cortex. (A) The C57 group neural cell was normal group as exhibited by intact membranes, uniform cytoplasm, and complete organelle structure. The AD group was showing that the nuclear shrinkage and deformed, the mitochondrial cristae fused with partial membranes, rough endoplasmic reticulum degranulated. The active compounds and DFO group were similar as C57 group. The ultrastructure of Epimedium, Astragaoside, and Puerarin group were similar, presenting partial neural edema or loss normal morphology, the nuclear shrinkage and deformed slightly(magnification:4000×). (B) The IOD value showing that the active compounds treatment reduces Aβ-42 expression in the AD model mouse frontal cortex. No significantly different between DFO and active compounds group. All data are expressed as the mean ± SD. Intergroup differences were compared with multivariate analysis of variance followed by the least significant difference test. (A) P < 0.05, vs. C57; (B) P < 0.05, vs. AD model; (C) P < 0.05, vs. DFO; (D) P < 0.05, vs. Active compounds; (E) P < 0.05, vs. Epimedium; (F) P < 0.05, vs. Astragaoside, P < 0.05, vs. Puerarin.